ArticleLeukemia & lymphoma2022

MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia.

Yue Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.